4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-012030
PRESIDENT AND CEO sold 7,500 shares at an average $20.06 ($150,415)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Kintz Samuel · PRESIDENT AND CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-05-01 | Sale : show line 1 in the form 10b5-1 | −5,330 | $20.08 | $107,007 | 980,062 | I |
| 2025-05-02 | Sale : show line 2 in the form 10b5-1 | −2,170 | $20.00 | $43,409 | 977,892 | I |
| Open-market sales · 7,500 sh · avg $20.06 · $150,415 | ||||||
Loading xslF345X05/form4-05052025_100514.xml…